Proteins that underlie neoplastic progression of ulcerative colitis

Proteomics - Clinical Applications

Volumn 3, Issue 11, 2009, Pages 1326-1337

  Brentnall, Teresa A ^a   Pan, Sheng ^a   Bronner, Mary P ^b   Crispin, David A ^a   Mirzaei, Hamid ^c   Cooke, Kelly ^c   Tamura, Yasuko ^a   Nikolskaya, Tatiana ^d,e   JeBailey, Lellean ^e   Goodlett, David R ^a   McIntosh, Martin ^f   Aebersold, Ruedi ^c,g   Rabinovitch, Peter S ^a   Chen, Ru ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

^e GeneGo bioinformatics software Inc   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Biomarker; Cancer; Dysplasia; Neoplastic progression; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CARBAMOYL PHOSPHATE SYNTHASE; MITOCHONDRIAL PROTEIN; MYC PROTEIN; PROTEIN S 100; PROTEIN S 100P; PROTEOME; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CARCINOGENESIS; CLINICAL ARTICLE; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DYSPLASIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; ULCERATIVE COLITIS;

EID: 77951049868     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900061     Document Type: Article

References (43)

1. Riddell, R. H., Goldman, H., Ransohoff, D. F., Appelman, H. D. et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 1983, 14, 931-968.
2. Rubin, C. E., Haggitt, R. C., Burmer, G. C., Brentnall, T. A. et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992, 103, 1611-1620.
3. Agoff, S. N., Brentnall, T. A., Crispin, D. A., Taylor, S. L. et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 2000, 157, 737-745.
4. Brentnall, T. A., Crispin, D. A., Rabinovitch, P. S., Haggitt, R. C. et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994, 107, 369-378.
5. Willenbucher, R. F., Zelman, S. J., Ferrell, L. D., Moore, D. H., Waldman, F. M., Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 1997, 113, 791-801.
6. Chen, R., Rabinovitch, P. S., Crispin, D. A., Emond, M. J. et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am. J. Pathol. 2003, 162, 665-672.
7. Issa, J. P., Ahuja, N., Toyota, M., Bronner, M. P., Brentnall, T. A., Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001, 61, 3573-3577.
8. O'Sullivan, J. N., Bronner, M. P., Brentnall, T. A., Finley, J. C. et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 2002, 32, 280-284.
9. Rabinovitch, P. S., Dziadon, S., Brentnall, T. A., Emond, M. J., et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res. 1999, 59, 5148-5153.
10. Felley-Bosco, E., Andre, M., Proteomics and chronic inflammatory bowel diseases. Pathol. Res. Pract. 2004, 200, 129-133.
11. Hsieh, S. Y., Shih, T. C., Yeh, C. Y., Lin, C. J. et al. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006, 6, 5322-5331.
12. Shkoda, A., Werner, T., Daniel, H., Gunckel, M. et al. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J. Proteome Res. 2007, 6, 1114-1125.
13. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
14. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics 2004, 3, 1154-1169.
15. Eng, J., McCormack, A. L., Yates, J. R., An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 1994, 5, 976-989.
16. Keller, A., Nesvizhskii, A. I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74, 5383-5392.
17. Elias, J. E., Haas, W., Faherty, B. K., Gygi, S. P., Comparative evaluation of mass spectrometry platforms used in largescale proteomics investigations. Nat. Methods 2005, 2, 667-675.
18. Deutsch, E. W., Lam, H., Aebersold, R., PeptideAtlas: A resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008, 9, 429-434.
19. Meany, D. L., Xie, H., Thompson, L. V., Arriaga, E. A., Griffin, T. J., Identification of carbonylated proteins from enriched rat skeletal muscle mitochondria using affinity chromatography-stable isotope labeling and tandem mass spectrometry. Proteomics 2007, 7, 1150-1163.
20. Dennis,G., Jr., Sherman, B. T., Hosack, D. A., Yang, J. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4, 3.
21. Risques, R. A., Lai, L. A., Brentnall, T. A., Li, L. et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 2008, 135, 410-418.
22. Gan, C. S., Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J. Proteome Res. 2007, 6, 821-827.
23. Nishikawa, M., Oshitani, N., Matsumoto, T., Nishigami, T., et al. Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br. J. Cancer 2005, 93, 331-337.
24. Kujoth, G. C., Bradshaw, P. C., Haroon, S., Prolla, T. A., The role of mitochondrial DNA mutations in mammalian aging. PLoS Genet. 2007, 3, e24.
25. Campisi, J., Aging, tumor suppression and cancer: high wire-act! Mech. Ageing Dev. 2005, 126, 51-58.
26. Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N. et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320, 661-664.
27. Wierstra, I., Sp1: emerging roles beyond constitutive activation of TATA-less housekeeping genes. Biochem. Biophys. Res. Commun. 2008, 372, 1-13.
28. Dideberg, V., Kristjansdottir, G., Milani, L., Libioulle, C., et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum. Mol. Genet. 2007, 16, 3008-3016.
29. Chen, R., Brentnall, T. A., Pan, S., Cooke, K. et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell Proteomics 2007, 6, 1331-1342.
30. Macpherson, A. J., Chester, K. A., Robson, L., Bjarnason, I. et al. Increased expression of c-myc proto-oncogene in biopsies of ulcerative colitis and Crohn's colitis. Gut 1992, 33, 651-656.
31. Pavelic, Z. P., Pavelic, L., Kuvelkar, R., Gapany, S. R., High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res. 1992, 12, 171-175.
32. Chu, E. C., Chai, J., Ahluwalia, A., Tarnawski, A. S., Mesalazine downregulates c-Myc in human colon cancer cells: a key to its chemopreventive action? Aliment Pharmacol. Ther. 2007, 25, 1443-1449.
33. Salama, I., Malone, P. S., Mihaimeed, F., Jones, J. L., A review of the S100 proteins in cancer. Eur. J. Surg. Oncol. 2008, 34, 357-364.
34. Brezova, A., Heizmann, C. W., Uhrik, B., Immunocytochemical localization of S100A1 in mitochondria on cryosections of the rat heart. Gen. Physiol. Biophys. 2007, 26, 143-149.
35. Ghavami, S., Kerkhoff, C., Chazin, W. J., Kadkhoda, K. et al. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim. Biophys. Acta 2008, 1783, 297-311.
36. Dowen, S. E., Crnogorac-Jurcevic, T., Gangeswaran, R., Hansen, M., et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am. J. Pathol. 2005, 166, 81-92.
37. Fuentes, M. K., Nigavekar, S. S., Arumugam, T., Logsdon, C. D. et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis. Colon. Rectum 2007, 50, 1230-1240.
38. Arumugam, T., Simeone, D. M., Van Golen, K., Logsdon, C. D., S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res. 2005, 11, 5356-5364.
39. Komatsu, K., Andoh, A., Ishiguro, S., Suzuki, N. et al. Increased expression of S100A6 (Calcyclin), a calciumbinding protein of the S100 family, in human colorectal adenocarcinomas. Clin. Cancer Res. 2000, 6, 172-177.
40. Mitchell, S., Ellingson, C., Coyne, T., Hall, L. et al. Genetic variation in the urea cycle: a model resource for investigating key candidate genes for common diseases. Hum. Mutat. 2008, 30, 56-60.
41. Wink, D. A., Ridnour, L. A., Hussain, S. P., Harris, C. C., The reemergence of nitric oxide and cancer. Nitric Oxide 2008, 19, 65-67.
42. Liu, T. H., Li, D. C., Gu, C. F., Ye, S. F., Carbamyl phosphate synthetase I: a novel marker for gastric carcinoma. Chin. Med. J. (Engl.) 1989, 102, 630-638.
43. Kinoshita, M., Miyata, M., Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology 2002, 36, 433-438.